Evidence map›Paper›PMID 39610825›Full record

ArticleMayo Clinic proceedings. Innovations, quality & outcomes2024

Post-Coronavirus Disease 2019 Effects in an Active University Population: A Within-Campus Cross-Sectional Study at a Major Educational Institution.

Marcelo Hernández-Mora, René Arredondo-Hernández, Carmen A Castañeda-Camacho, Pamela X Cervantes-Gutierrez, Gonzalo Castillo-Rojas, Samuel Ponce de León, Yolanda López-Vidal

Abstract read
In one paragraph

Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marcelo Hernández-MoraMD, Center for SARS-CoV-2 Diagnosis for the University Community, National Autonomous University of Mexico, Mexico City, Mexico.
René Arredondo-HernándezMicrobiome Laboratory, Research Division, National Autonomous University of Mexico, Mexico City, Mexico.
Carmen A Castañeda-CamachoMD, Center for SARS-CoV-2 Diagnosis for the University Community, National Autonomous University of Mexico, Mexico City, Mexico.
Pamela X Cervantes-GutierrezMD, Center for SARS-CoV-2 Diagnosis for the University Community, National Autonomous University of Mexico, Mexico City, Mexico.
Gonzalo Castillo-RojasMicrobial Molecular Immunology Program, Department of Microbiology and Parasitology, National Autonomous University of Mexico, Mexico City, Mexico.
Samuel Ponce de LeónMicrobiome Laboratory, Research Division, National Autonomous University of Mexico, Mexico City, Mexico.
Yolanda López-VidalMD, Center for SARS-CoV-2 Diagnosis for the University Community, National Autonomous University of Mexico, Mexico City, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To evaluate the associations among post-coronavirus disease 2019 (COVID-19) prevalence; risk factors and comorbidities have not been firmly established within a university outpatient population. Patients and Methods: Records from 881 COVID-19 outpatient patients (504 females [57.9%] and 366 males [42.07%]), most of whom were between 30 and 40 years of age (mean=37.3 years old; 95% CI, 36.5-38.2), with initial infection data from February 2020 to August 2022 were reviewed once, whereas the survey took place during 2 different moments during the pandemic. The first period (April 20, 2021, to June 21, 2021) yielded 279 responses, whereas in the second period (June 23, 2021, to October 4, 2021), 602 responses were recorded. The instrument used contained 20 questions across 3 main domains: general information, data related to infection and adverse effects, and service satisfaction experience. Results: All the patients were positive for immunoglobulin G antibodies against nucleocapsid by the third week. Post-COVID-19 symptoms arose at least 2 weeks after recovery from the initial illness; 654 individuals reported at least one symptom after the acute COVID-19 period, for a post-COVID-19 prevalence of 74.96%. The most frequent symptoms were fatigue (84%), headache (71%), and difficulty concentrating (71%). More than 60% of participants reported at least one comorbidity, among which the most common ones were obesity (35.9%), smoking (17.5%), and hypertension (12.2%). Conclusion: In this study, we assessed post-COVID-19 prevalence among outpatients and found that comorbidities were strongly related to consequences impacting quality of life and mental health burden.

Identifiers

PMID39610825
PMCPMC11603001

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.